See ratings and reviews when you sign up for an account.

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)

This study is currently Recruiting

August 2011 By University of Virginia

First Recieved on August 30, 2011

Last Updated on August 31, 2011

Sponsor: University of Virginia
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: University of Virginia
Identifier: NCT01427595


Many, but not all, girls with high levels of the male hormone testosterone go on to develop polycystic ovary syndrome (PCOS) as adults. Women with PCOS often have irregular menstrual periods, excess facial and body hair, and weight gain. PCOS is also a leading cause of difficulty becoming pregnant. The investigators do not understand why some girls with high hormones develop PCOS and others do not. In a previous study by our group, some girls with high levels of male hormones had abnormalities in the secretion of another hormone (called LH) that are often seen in women with PCOS. However, another group had normal LH secretion. The girls with the abnormal LH secretion had higher levels of another hormone, called insulin, than the girls with normal LH secretion. The investigators will test whether Metformin, an insulin-sensitizing agent, changes the effects of high male hormone levels in adolescent girls, specifically by looking at their LH secretion response following metformin treatment.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Ages Eligible for Study:10 Years
Genders Eligible for Study:Female
Accepts Healthy Volunteers:No

Inclusion Criteria: - Girls ages 10 to 17 - Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage) - Creatinine clearance > 90 ml/min as calculated by the Cockcroft-Gault equation - Hemoglobin > 12 mg/dL or Hematocrit > 36% - Normal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia) - Sexually active subjects must agree to abstain or use double barrier contraception during the study - Subjects must agree not to take any other medications during the course of the study without approval by the study investigators. Exclusion Criteria: - Abnormal screening labs (with the exception of the expected hormonal abnormalities inherent in hyperandrogenemia) - Creatinine clearance less than 90 ml/min as calculated by Cockcroft-Gault equation - Hemoglobin <12 mg/dL or hematocrit < 36% - Abnormal liver function tests (including AST, ALT, Bilirubin, Albumin, and Alkaline Phosphatase) - Weight < 34 kg - History of renal dysfunction, liver dysfunction, congestive heart failure, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer - Pregnant or breast feeding - On medications known to affect the reproductive axis within 3 months of the study (including oral contraceptive pills, metformin, and spironolactone) - Are currently participating in another study or have been in one in the last 30 days. - Subjects using restricted medication (see restrictions below) are excluded unless the subject's primary care provider approves stopping the medication.


  • Investigator: John C. Marshall, MD, PhD - Principal Investigator - University of Virginia


  • Center for Research in Reproduction, University of Virginia

    Charlottesville, Virginia 22908 United States

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.